Crinetics Pharmaceuticals-2026-JPM.pdf

1、JANUARY 2026Beyond Innovation to Impact:Building the Premier Endocrinology BusinessJ.P.Morgan Healthcare ConferenceAngela Living with AcromegalyForward Looking Statements and Legal DisclaimersForward Looking Statements:This presentation contains forward-looking statements.Crinetics Pharmaceuticals,I

2、nc.(“Crinetics,”the“company,”“we,”“us,”or“our”)cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements.Such forward-looking statements include,but are not limited to,statements regarding:our ability to effectively comme

3、rcialize PALSONIFY(paltusotine)to become a market leader or a“blockbuster”;our estimates relating to market size,or our ability to drive diagnosis and treatment for undiagnosed patients;the plans and timelines approval of paltusotine outside the US;the plans and timelines for a Phase 3 program,regul

4、atory filings or approval of paltusotine for carcinoid syndrome,for atumelnant for CAH and for atumelnant for ACTH-dependent Cushings syndrome;the ability of atumelnant to transform CAH treatment or to become a“blockbuster”therapy for CAH;the ability of CRN09682 to become a“blockbuster”for neuroendo

5、crine tumors or other SST2+tumors;the plans and timelines for the clinical development of our drug candidates,including the therapeutic potential and clinical benefits or safety profile thereof;and the expected timing for the initiation of clinical trials or the potential benefits of our development

6、 candidates in patients across multiple indications;the expected timing of additional research pipeline updates or the expected timing of the advancement of those programs;and the expected timing through which our cash,cash equivalents,and short-term investments will fund our operating plans or its